237 related articles for article (PubMed ID: 35379762)
1. Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
Leppert D; Kropshofer H; Häring DA; Dahlke F; Patil A; Meinert R; Tomic D; Kappos L; Kuhle J
Neurology; 2022 May; 98(21):e2120-e2131. PubMed ID: 35379762
[TBL] [Abstract][Full Text] [Related]
2. Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study.
Gold R; Piani-Meier D; Kappos L; Bar-Or A; Vermersch P; Giovannoni G; Fox RJ; Arnold DL; Benedict RHB; Penner IK; Rouyrre N; Kilaru A; Karlsson G; Ritter S; Dahlke F; Hach T; Cree BAC
J Neurol; 2022 Sep; 269(9):5093-5104. PubMed ID: 35639197
[TBL] [Abstract][Full Text] [Related]
3. Response to ibudilast treatment according to progressive multiple sclerosis disease phenotype.
Goodman AD; Fedler JK; Yankey J; Klingner EA; Ecklund DJ; Goebel CV; Bermel RA; Chase M; Coffey CS; Klawiter EC; Naismith RT; Fox RJ;
Ann Clin Transl Neurol; 2021 Jan; 8(1):111-118. PubMed ID: 33460301
[TBL] [Abstract][Full Text] [Related]
4. Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials.
Harris S; Comi G; Cree BAC; Arnold DL; Steinman L; Sheffield JK; Southworth H; Kappos L; Cohen JA;
Eur J Neurol; 2021 Nov; 28(11):3722-3730. PubMed ID: 34292643
[TBL] [Abstract][Full Text] [Related]
5. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.
Kappos L; Bar-Or A; Cree BAC; Fox RJ; Giovannoni G; Gold R; Vermersch P; Arnold DL; Arnould S; Scherz T; Wolf C; Wallström E; Dahlke F;
Lancet; 2018 Mar; 391(10127):1263-1273. PubMed ID: 29576505
[TBL] [Abstract][Full Text] [Related]
6. Indirect comparisons of siponimod with fingolimod and ofatumumab in multiple sclerosis: assessing the feasibility of propensity score matching analyses.
Samjoo IA; Worthington E; Haltner A; Spin P; Drudge C; Cameron C; Brennan R; Dahlke F; Adlard N
Curr Med Res Opin; 2021 Nov; 37(11):1933-1944. PubMed ID: 34384311
[TBL] [Abstract][Full Text] [Related]
7. Effects of baseline age and disease duration on the efficacy and safety of siponimod in patients with active SPMS: Post hoc analyses from the EXPAND study.
Hua LH; Bar-Or A; Cohan SL; Lublin FD; Coyle PK; Cree BA; Meng X; Su W; Cox GM; Fox RJ
Mult Scler Relat Disord; 2023 Jul; 75():104766. PubMed ID: 37245350
[TBL] [Abstract][Full Text] [Related]
8. Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial.
Kuhle J; Chitnis T; Banwell B; Tardieu M; Arnold DL; Rawlings AM; Geertsen SS; Lublin AL; Saubadu S; Truffinet P; Kappos L
Mult Scler; 2023 Mar; 29(3):385-394. PubMed ID: 36632983
[TBL] [Abstract][Full Text] [Related]
9. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
Lublin F; Miller DH; Freedman MS; Cree BAC; Wolinsky JS; Weiner H; Lubetzki C; Hartung HP; Montalban X; Uitdehaag BMJ; Merschhemke M; Li B; Putzki N; Liu FC; Häring DA; Kappos L;
Lancet; 2016 Mar; 387(10023):1075-1084. PubMed ID: 26827074
[TBL] [Abstract][Full Text] [Related]
10. Disability accrual in primary and secondary progressive multiple sclerosis.
Harding-Forrester S; Roos I; Nguyen AL; Malpas CB; Diouf I; Moradi N; Sharmin S; Izquierdo G; Eichau S; Patti F; Horakova D; Kubala Havrdova E; Prat A; Girard M; Duquette P; Grand'Maison F; Onofrj M; Lugaresi A; Grammond P; Ozakbas S; Amato MP; Gerlach O; Sola P; Ferraro D; Buzzard K; Skibina O; Lechner-Scott J; Alroughani R; Boz C; Van Pesch V; Cartechini E; Terzi M; Maimone D; Ramo-Tello C; Yamout B; Khoury SJ; La Spitaleri D; Sa MJ; Blanco Y; Granella F; Slee M; Butler E; Sidhom Y; Gouider R; Bergamaschi R; Karabudak R; Ampapa R; Sánchez-Menoyo JL; Prevost J; Castillo-Trivino T; McCombe PA; Macdonell R; Laureys G; Van Hijfte L; Oh J; Altintas A; de Gans K; Turkoglu R; van der Walt A; Butzkueven H; Vucic S; Barnett M; Cristiano E; Hodgkinson S; Iuliano G; Kappos L; Kuhle J; Shaygannejad V; Soysal A; Weinstock-Guttman B; Van Wijmeersch B; Kalincik T;
J Neurol Neurosurg Psychiatry; 2023 Sep; 94(9):707-717. PubMed ID: 37068931
[TBL] [Abstract][Full Text] [Related]
11. Effects of Ibudilast on Retinal Atrophy in Progressive Multiple Sclerosis Subtypes: Post Hoc Analyses of the SPRINT-MS Trial.
Ehrhardt H; Lambe J; Moussa H; Vasileiou ES; Kalaitzidis G; Murphy OC; Filippatou AG; Pellegrini N; Douglas M; Davis S; Nagy N; Quiroga A; Hu C; Zambriczki Lee A; Duval A; Fitzgerald KC; Prince JL; Calabresi PA; Sotirchos ES; Bermel R; Saidha S
Neurology; 2023 Sep; 101(10):e1014-e1024. PubMed ID: 37460235
[TBL] [Abstract][Full Text] [Related]
12. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
13. Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis.
Manouchehrinia A; Stridh P; Khademi M; Leppert D; Barro C; Michalak Z; Benkert P; Lycke J; Alfredsson L; Kappos L; Piehl F; Olsson T; Kuhle J; Kockum I
Neurology; 2020 Jun; 94(23):e2457-e2467. PubMed ID: 32434867
[TBL] [Abstract][Full Text] [Related]
14. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study.
Pöhlau D; Przuntek H; Sailer M; Bethke F; Koehler J; König N; Heesen C; Späth P; Andresen I
Mult Scler; 2007 Nov; 13(9):1107-17. PubMed ID: 17623736
[TBL] [Abstract][Full Text] [Related]
15. Neurofilament Light Chain Levels Are Associated with Disease Activity Determined by No Evident Disease Activity in Multiple Sclerosis Patients.
Szilasiová J; Rosenberger J; Fedičová M; Mikula P; Urban P; Gdovinová Z; Vitková M; Hanes J; Stevens E
Eur Neurol; 2021; 84(4):272-279. PubMed ID: 34034261
[TBL] [Abstract][Full Text] [Related]
16. Neurofilament light chain and MRI volume parameters as markers of neurodegeneration in multiple sclerosis.
Filippi P; Vestenická V; Siarnik P; Sivakova M; Čopíková-Cudráková D; Belan V; Hanes J; Novák M; Kollar B; Turcani P
Neuro Endocrinol Lett; 2020 Apr; 41(1):17-26. PubMed ID: 32338853
[TBL] [Abstract][Full Text] [Related]
17. Associations between neurofilament light chain levels, disease activity and brain atrophy in progressive multiple sclerosis.
Szilasiova J; Mikula P; Rosenberger J; Fedicova M; Urban P; Frigova L; Vitkova M; Gdovinova Z; Hanes J; Stevens E
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 Sep; 166(3):304-311. PubMed ID: 34092793
[TBL] [Abstract][Full Text] [Related]
18. Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial.
Arnold DL; Piani-Meier D; Bar-Or A; Benedict RH; Cree BA; Giovannoni G; Gold R; Vermersch P; Arnould S; Dahlke F; Hach T; Ritter S; Karlsson G; Kappos L; Fox RJ;
Mult Scler; 2022 Sep; 28(10):1526-1540. PubMed ID: 35261318
[TBL] [Abstract][Full Text] [Related]
19. Assessing Neurofilaments as Biomarkers of Neuroprotection in Progressive Multiple Sclerosis: From the MS-STAT Randomized Controlled Trial.
Williams TE; Holdsworth KP; Nicholas JM; Eshaghi A; Katsanouli T; Wellington H; Heslegrave A; Zetterberg H; Frost C; Chataway J
Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35031587
[TBL] [Abstract][Full Text] [Related]
20. Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials.
Bar-Or A; Thanei GA; Harp C; Bernasconi C; Bonati U; Cross AH; Fischer S; Gaetano L; Hauser SL; Hendricks R; Kappos L; Kuhle J; Leppert D; Model F; Sauter A; Koendgen H; Jia X; Herman AE
EBioMedicine; 2023 Jul; 93():104662. PubMed ID: 37354600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
